You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 13, 2024

Litigation Details for Novo Nordisk, Inc. v. Mylan Pharmaceuticals, Inc. (D. Del. 2022)

✉ Email this page to a colleague

« Back to Dashboard

Novo Nordisk, Inc. v. Mylan Pharmaceuticals, Inc. (D. Del. 2022)

Docket	⤷ Sign Up	Date Filed	2022-08-08
Court	District Court, D. Delaware	Date Terminated	2024-10-02
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	None	Referred To	Eleanor G. Tennyson
Patents	10,220,155; 10,335,462; 10,357,616; 10,376,652; 8,114,833; 8,129,343; 8,536,122; 8,684,969; 8,920,383; 9,108,002; 9,132,239; 9,457,154; 9,616,180; 9,687,611; 9,775,953; 9,861,757; RE46,363
Link to Docket	External link to docket

Small Molecule Drugs cited in Novo Nordisk, Inc. v. Mylan Pharmaceuticals, Inc.

The small molecule drugs covered by the patents cited in this case are ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , and ⤷ Sign Up .

Biologic Drugs cited in Novo Nordisk, Inc. v. Mylan Pharmaceuticals, Inc.

The biologic drugs covered by the patents cited in this case are ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , and ⤷ Sign Up .

Details for Novo Nordisk, Inc. v. Mylan Pharmaceuticals, Inc. (D. Del. 2022)

+ Get email alerts for changes to this table

Subscribe to access the full database, or Sign Up
Date Filed	Document No.	Description	Snippet	Link To Document
0000-00-00				External link to document
2022-03-18	1		1/09/2018 Novo Nordisk A/S 13 10,220,155 3/05/2019 Novo…following n Trademarks or BfPatents. ( Q the patent action involves 35 U.S.C. § 292.): DOCKET…PHARMACEUTICALS INC. PATENT OR DATE OF PATENT … □ Other Pleading PATENT OR DATE OF PATENT …INC. NOVO NORDISK A/S PATENT OR DATE OF PATENT	External link to document
2023-08-03	118	Notice of Service	Contentions Regarding U.S. Patent Nos. 8,129,343; 8,536,122; 8,114,833; 8,920,383; 9,775,953; 9,457,154; …2022 2 October 2024 1:22-cv-01040 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2024-01-10	182	Notice of Service	Disclosure of Asserted Patents and Claims as to MPI Regarding U.S. Patent Nos. 8,920,383 and 9,775,953 filed…2022 2 October 2024 1:22-cv-01040 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2024-01-19	185	Notice of Service	Asserted Claims for U.S. Patent No. 8,950,383 and U.S. Patent No. 9,775,953 to Defendant Mylan Pharmaceuticals…2022 2 October 2024 1:22-cv-01040 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2024-02-12	191	Notice of Service	Invalidity Contentions Regarding U.S. Patent Nos. 8,129,343; 8,536,122; and 10,335,462 - filed by Novo Nordisk…2022 2 October 2024 1:22-cv-01040 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
>Date Filed	>Document No.	>Description	>Snippet	>Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.